Cell activation markers in rhinitis and rhinosinusitis: Part I: Eosinophil cationic protein;ZELLAKTIVIERUNGSMARKER BEI RHINITIS UND RHINOSINUSITIS. TEIL 1: EOSINOPHILES KATIONISCHES PROTEIN (ECP)

Laryngo- Rhino- Otologie

Volumn 75, Issue 11, 1996, Pages 665-670

  Klimek, L ^a   Rasp, G ^b  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cell activation markers; Eosinophil cationic protein; Inflammation; Nasal polyps; Nasal secretions; Rhinitis; Sinusitis

Indexed keywords

EOSINOPHIL CATIONIC PROTEIN;

ADULT; ALLERGIC RHINITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EOSINOPHIL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NOSE POLYP; NOSE SECRETION; PARANASAL SINUSITIS; PRIORITY JOURNAL;

EID: 0029972214     PISSN: 09358943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-997654     Document Type: Article

References (58)

1. Adelroth, E., L. Rosenhall, S. A. johansson, M. Linden, P. Venge: inflammatory Cells and eosinophil activity in asthmatics investigated by bronchoalveolar lavage. Am. Rev. Resp. Dis. 142 (1990) 91-99
2. Andersson, M., P. Andersson, P. Venge, U. Pipkorn: Eosinophils and eosinophil cationic protein in nasal lavages in allergen-induced hyperresponsiveness: effects of topical glucocorticosteroid treatment. Allergy 44 (1989) 342-348
3. Ayars, G. H., L. C. Altman, M. M. McManus, J. M. Agosti, C. Baker, D. L. Luchtel, D. A. Loegering, G. J. Gleich: Injurious effect of the eosinophil peroxide-hydrogen peroxide-halide system and major basic protein on human nasal epithelium in vitro. Am. Rev. Respir. Dis. 140 (1989) 125-131
4. Bachert, C. U. Ganzer: Allergische Rhinitis: Zellen und Mediatoren in der Sofort- und Spätphase. Teil I. Otorhinolaryngol. Nova 1 (1991) 46-52
5. Bachert, C. U. Ganzer: Allergische Rhinitis: Zellen und Mediatoren in der Sofort- und Spätphase. Teil II. Otorhinolaryngol. Nova 1 (1991) 69-74
6. Bascom, R., U. Pipkorn, G. Gleich. I. M. Lichtenstein, R. M. Naclerio: The influx of inflammatory cells into nasal washings during the late response to antigen challenge. Effect of systemic steroid pretreatment. Am. Rev. Resp. Dis. 138 (1988) 406-412
7. Bahre, M., L. Klimek, J. Mölich, R. Mösges: Azelastine reduces release of Eosinophil Cationic Protein (ECP). In Basomba, A., M. D. Hernandez, F. Rojas de (Hrsg.): Proceedings II of the ECACI '95. Monduzzi Editore, Bologna 1995 (859-862)
8. Bisgaard, H., H. Gronborg, N. Mygind, R. Dahl, N. Lindquist, P. Venge: Allergen-induced increase of eosinophil cationic protein in nasal lavage fluid: effect of the glucocorticoid budesonide. J. Allergy Gin. Immunol. 85 (1990) 891-895
9. Bonini, S., M. Tomassini, E. Adriani, L. Magrini, C. Rumi, S. Bussa, F. Ronchetti, S. Bonini: Markers of eosinophilic inflammation in allergic diseases. Allergy 48 (1993) 133-137
10. Capron, M.: Eosinophils: Receptors and mediators in hypersensitivity. Clin. Exp. Allergy 19 (Suppl. 1) (1989) 3-8
11. Castells, M. C., L. B. Schwartz: Tryptase levels in nasal lavage fluid as an indicator of the immediate allergic response. J. Allergy Clin. Immunol. 82 (1988) 348-355
12. Czech, W., J. Krutmann, E. Schöpf, A. Kapp: Serum eosinophil cationic protein (ECP) is a sensitive measure for disease activity in atopic dermatitis. Br. J. Dermatol. 126 (1992) 351-355
13. Dahl, R.: Eosinophil and eosinophil products. In Mygind, N., U. Pipkorn (Eds.): Allergic and vasomotor rhinitis: pathophysiological aspects. Munksgaard, Copenhagen, Denmark 1987 (136-139)
14. Ding-E Young, J., C. G. B. Peterson, P. Venge, Z. A. Cohn: Mechanism of membrane damage mediated by human eosinophil cationic protein. Nature 321 (1986) 613-616
15. Ehrlich, P.: Beiträge zur Kenntnis der granulierenden Bindegewebszellen und der eosinophilen Leukozyten. Arch. Anat. Physiol. (1879) 166-177
16. Fujisawa, T., R. Abu-Ghazaleh, H. Kita, C. J. Sanderson, G. J. Gleich: Regulatory effect of cytokines on eosinophil degranulation. J. Immunol. 144 (1989) 642-646
17. Gleich, G. J., C. R. Adolphson: The eosinophil leukocyte: structure and function. Adv. Immunol. 39 (1986) 177-253
18. Griffin, E., L Hakansson, H. Formgrea, K. Jorgensen, C. Peterson, P. Venge: Blood eosinophil number and activity in relation to lung function in asthmatic patients with eosinophilia. J. Allergy Clin. Immunol. 87 (1991) 548-557
19. Harlin, S. L., D. G. Ansel, S. R. Lane, J. Myers, G. M. Kephart, G. J. Gleich: A clinical and pathologic study of chronic sinusitis: the role of the eosinophil. J. Allergy Clin. Immunol. 81 (1988) 867-875
20. Heppt, W. (Hrsg.): Zytologie der Nasenschleirnhaut. Springer-Verlag, Berlin, Heidelberg, New York (1995)
21. Holopainen, E.: Nasal Cytology as a nasal test. Rhinology 14 (1976) 29-35
22. Jakob, T., K. Hermann, J. Ring: Eosinophil cationic protein in atopic eczema. Arch. Dermatol. Res. 283 (1991) 5-6
23. Kapp, A.: The role of eosinophils in the pathogenesis of atopic dermatitis - eosinophil granule proteins as markers of disease activity. Allergy 48 (1993) 1-5
24. Klimek, L. H. Riechelmann, W. Prellwitz: Einfluβ einer Hyposensibilisierung auf Tryptase und ECP in Nasensekret und Blutserum bei Birkenpollenallergikern. HNO Informationen 20 (1995) 131
25. Klimek, L., H. Riechelmann: Zellaktivieningsmarker bei Rhinitis allergica. In Mösges, R., G. Schlöndorff (Hrsg.): Die Folgen der Allergie-Rhinitis, Asthma, Polyposis nasi. Biermann-Thieme Verlag 1996 (52-59)
26. Klimek, L., H. Riechelmann, A. K. Olbrich: Effekt einer präsaisonalen Kurzzeit-Hyposensibilisierung mit Allergenextrakten bei allergischer Rhinitis ein Jahr nach Therapieende. Allergologie 3 (1996) 152
27. Klimek, L., H. Riechelmann, R. Amedee: Eosinophil Cationic Protein in nasal secretions and blood serum in grass-pollen allergic rhinitis. Am. J. Rhinol. (1996) (in press)
28. Kroegel, C., H. Matthys: Mit dem eosmophilen Granulozyten assoziierte Erkrankungen. Arzneimitteltherapie 10 (1992) 140-150
29. Leiferman, K. M.: A current perspective on the role of eosinophils in dermatologic diseases, J. Am. Acad. Dermatol. 24 (1991) 1101-1112
30. Under, A., P. Venge, H. Deuschl: Eosinophil cationic protein and myeloperoxidase in nasal secretion as markers of inflammation in allergic rhinitis. Allergy 42 (1987) 583-590
31. Nishioka, K., C. Saito, T. Nagano, M. Okano, Y. Masuda, T. Kuriyama: Eosinophil Cationic Protein in the nasal secretions of patients with mite allergic rhinitis. Laryngoscope 103 (1993) 189-192
32. Olofsson, T., I. Olsson, P. Venge, B. Elgefors: Serum myeloper-oxidase and lactoferrin in neutropenia. Scand. J. Haematol. 18 (1977) 73-80
33. Osgood, E. E.: Number and distribution of human hemic cells. Blood 9 (1954) 1141-1149
34. Parwaresch, M. R., A. J. Walle, D. Arndt: The peripheral kinetics of human radiolabelled eosinophils. Virchows Arch. Cell Pathol. 21 (1976) 57-66
35. Pedersen, B., R. Dahl, B. B. Larsen, P. Venge: The effect of salmeterol on the early- and late-phase reaction to bronchial allergen and postchallenge variation in bronchial reactivity, blood eosinophils, serum eosinophil cationic protein, and serum eosinophil protein X. Allergy 48 (1993) 377-382
36. Pelikan, Z., A. Pelikan, M. Filipek: Cytologic changes in the nasal secretions during the immediate nasal response. J. Allergy Clin. Immunol. 82 (1988) 1103-1112
37. Pelikan, Z., A. Pelikan, M. Filipek: Cytologic changes in the nasal secretions during the late nasal response. J. Allergy Clin. Immunol. 83 (1989) 1068-1078
38. Peterson, G. B., I. Enander, J. Nystrand, A. S. Anderson, L. Nilsson, P. Venge: Radioimmunoassay of human eosinophil canonic protein (ECP) by an improved method. Establishment of normal levels and turnover in vivo. Clin. Exp. Allergy 21 (1991) 561-567
39. Pharmacia: ECP-RIA - Gebrauchsinformation. Kabi Pharmacia Diagnostics AB, Uppsala, Schweden (1992)
40. Pipkorn, U., G. Karlsson, L. Enerback: The cellular response of the human allergic mucosa to natural allergen exposure. J. Allergy Clin. Immunol. 82 (1988) 1046-1054
41. Prin, L., M. Capron, A. B. Tonnel, O. Bletry, A. Capron: Heterogeneity to human peripheral blood eosinophils: variability in cell density and cytotoxic ability in relation to the level and the origin of hypereosinophilia. Int. Arch. Allergy Appl. Immunol. 72 (1983) 336-346
42. Prin, L., J. Charon, M. Capron, P. Gosset, H. Taelman, A. B. Tonnel, A. Capron: Heterogeneity of human eosinophils II. Variability of respiratory burst activity related to cell density. Clin. Exp. Immunol. 57 (1984) 735-742
43. Rak, S., O. Löwhagen, P. Venge: The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients. J. Allergy Clin. Immunol. 82 (1988) 470-480
44. Rak, S., A. Björnson, L. Hakansson, S. Sörenson, P. Venge: The effect of immunotherapy on eosinophil accumulation and production of eosinophil chemotactic activity in the lung of subjects with asthma during natural pollen exposure. J. Allergy Clin. Immunol. 88 (1991) 878-888
45. Rasp, G., K. Hochstrasser: Tryptase in nasal fluid is a useful marker of allergic rhinitis. Allergy 48 (1993) 72-74
46. Rasp, G., B. A. Thomas, J. Bujía: Eosinophil inflammation of the nasal mucosa in allergic and non-allergic rhinitis measured by eosinophil cationic protein levels in native nasal fluid and serum. Clin. Exp. Allergy 24 (1994) 1151-1156
47. Schmekel, B., P. Venge: Markers for eosinophils and T-lymphocytes as predictors of late asthmatic response. Allergy 48 (1993) 94-97
48. Schwartz, L. B.: Mediators of human mast cells and human mast cells subsets. Ann. Allergy 58 (1987) 226-237
49. Schwartz, L. B.: Tryptase, a mediator of human mast cells. J. Allergy Clin. Immunol. 86 (1990) 594-598
50. Tai, P. C., C. J. F. Spry, C. Peterson, P. Venge. I. Olsson: Monoklonal antibodies distinguish between storage and secreted forms of eosinophil cationic protein. Nature 309 (1984) 182-184
51. Toorerenbergen van, A. W., R. G. van Wijk , A. M. Vermeulen, F. J. Zijlstra: Increase of albumin, eosinophil cationic protein, histamine, leukotriens and mast cell tryptase in nasal lavage fluid after challenge with inhalant allergen extract Agents Actions 8 (1992) 421-424
52. Venge, P., L E. Roxin, I. Olsson: Radioimmunoassay of human eosinophil cationic protein. Br. J. Haematol. 37 (1977) 331-335
53. Venge, P., R. Dahl, C. G. B. Peterson: Eosinophil granule proteins in serum after allergen challenge of asthmatic patients and the effects of anti-asthmatic medication. Int. Arch. Allergy Appl. Immunol. 87 (1988) 306-312
54. Venge, P., J. Henriksen, R. Dahl: Eosinophils in exercise-induced asthma. J. Allergy Clin. Immunol. 88 (1991) 699-704
55. Venge, P.: Eosinophil and neutrophil granulocytes. Allergy 48 (1993) 39-47
56. venge, P.: Soluble markers of allergic inflammation. Allergy 49 (1994) 1-8
57. Wenzel, S., A. M. Irani, S. M. Sanders, T. R. Bradford, L. B. Schwartz: Immunoassay of tryptase from human mast cells. J. Immunol. Methods 86 (1986) 139-142
58. Winqvist, I., T. Olofsson, I. Olsson: Mechanisms for eosinophil degranulation; release of eosinophil cationic protein. Immunology 51 (1984) 1-8